The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant
Open accessAbstract
The BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines generate potent neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the global emergence of SARS-CoV-2 variants with mutations in the spike protein, the principal antigenic target of these vaccines, has raised concerns over the neutralizing activity of vaccine-induced antibody responses. The Omicron variant, which emerged in November 2021, consists of over 30 mutations within the spike protein. Here, we used an authentic live virus neutralization assay to examine the neutralizing activity of the SARS-CoV-2 Omicron variant against mRNA vaccine-induced antibody responses. Following the 2nd dose, we observed a 30-fold reduction in neutralizing activity against the omicron variant. Through six months after the 2nd dose, none of the sera from naïve vaccinated subjects showed neutralizing activity against the Omicron variant. In contrast, recovered vaccinated individuals showed a 22-fold reduction with more than half of the subjects retaining neutralizing antibody responses. Following a booster shot (3rd dose), we observed a 14-fold reduction in neutralizing activity against the omicron variant and over 90% of boosted subjects showed neutralizing activity against the omicron variant. These findings show that a 3rd dose is required to provide robust neutralizing antibody responses against the Omicron variant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Self-citationAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Self-citationAn Infectious cDNA Clone of SARS-CoV-2
Xie, X., Muruato, A., Lokugamage, K. G., Narayanan, K., Zhang, X., Zou, J., Liu, J., Schindewolf, C., Bopp, N. E., Aguilar, P. V., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.004 · Cited by 647
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., Campbell, T. B., Clark, J., Jackson, L. A., Fichtenbaum, C. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113017 · Cited by 641
Self-citationDurability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
Pegu, A., O’Connell, S. E., Schmidt, S. D., O’Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., et al. (2021) · Science · doi:10.1126/science.abj4176 · Cited by 527
Self-citationPlasma Neutralization of the SARS-CoV-2 Omicron Variant
Schmidt, F., Muecksch, F., Weisblum, Y., Da Silva, J., Bednarski, E., Cho, A., Wang, Z., Gaebler, C., Caskey, M., Nussenzweig, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119641 · Cited by 432
Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants
Edara, V.-V., Pinsky, B. A., Suthar, M. S., Lai, L., Davis-Gardner, M. E., Floyd, K., Flowers, M. W., Wrammert, J., Hussaini, L., Ciric, C. R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2107799 · Cited by 328
Self-citation
Cited by
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
Shuai, H., Chan, J. F.-W., Hu, B., Chai, Y., Yuen, T. T.-T., Yin, F., Huang, X., Yoon, C., Hu, J.-C., Liu, H., et al. (2022) · Nature · doi:10.1038/s41586-022-04442-5 · Cited by 654
Shrestha, L. B., Foster, C., Rawlinson, W., Tedla, N., & Bull, R. A. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2381 · Cited by 474
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
Lyke, K. E., Atmar, R. L., Islas, C. D., Posavad, C. M., Szydlo, D., Paul Chourdhury, R., Deming, M. E., Eaton, A., Jackson, L. A., Branche, A. R., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100679 · Cited by 153
Self-citationPost-Vaccination Neutralization Responses to Omicron Sub-Variants
Jacobsen, H., Katzmarzyk, M., Higdon, M. M., Jiménez, V. C., Sitaras, I., Bar-Zeev, N., & Knoll, M. D. (2022) · Vaccines · doi:10.3390/vaccines10101757 · Cited by 21
Sitaras, I., Jacobsen, H., Higdon, M. M., Dowling, W. E., Bar-Zeev, N., & Deloria Knoll, M. (2022) · npj Vaccines · doi:10.1038/s41541-022-00565-y · Cited by 17
Metadata
- Authors
- Edara, V.-V., Manning, K. E., Ellis, M., Lai, L., Moore, K. M., Foster, S. L., Floyd, K., Davis-Gardner, M. E., Mantus, G., Nyhoff, L. E., Bechnak, S., Alaaeddine, G., Naji, A., Samaha, H., Lee, M., Bristow, L., Gagne, M., Roberts-Torres, J., Henry, A. R., Godbole, S., Grakoui, A., Saxton, M., Piantadosi, A., Waggoner, J. J., Douek, D. C., Rouphael, N., Wrammert, J., & Suthar, M. S.
- Venue
- Cell Reports Medicine
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 3
- Issue
- 2
- Pages
- 100529
- ISSN
- 2666-3791 (ISSN-L)
- OpenAlex
- W4220770780
- Cited by
- 213
- References
- 7
- FWCI
- 23.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant. https://app.cochat.ai/papers/10.1016/j.xcrm.2022.100529
- The paper
- Edara, V.-V., Manning, K. E., Ellis, M., Lai, L., Moore, K. M., Foster, S. L., Floyd, K., Davis-Gardner, M. E., Mantus, G., Nyhoff, L. E., Bechnak, S., Alaaeddine, G., Naji, A., Samaha, H., Lee, M., Bristow, L., Gagne, M., Roberts-Torres, J., Henry, A. R., . . . Suthar, M. S. (2022). mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant. Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2022.100529
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.